PD-L1, PD-1, and CTLA-4 Expression as Predictors of Response to Monotherapy With Nivolumab or Ipilimumab in Advanced-Stage Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma
Am J Dermatopathol 2020 Dec 29;[EPub Ahead of Print], A Santos-Briz, J Cañueto, SD Carmen, B Barrios, M Yuste, L Bellido, MD Ludeña, C RománFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.